TYR and melanoma: (136) recently conducted at phase 1 trial (NCT02410733) in melanoma patients who received melanoma FixVac (BNT111) an intravenously administered liposomal RNA (RNA-LPX) vaccine that targets four tumor associated antigens (NY-ESO-1, MAGE-A3, tyrosinase and TPTE) (135).